Literature DB >> 15996946

Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice.

Ka Lung Wu, Wessel van Wieringen, Edo Vellenga, Sonja Zweegman, Henk M Lokhorst, Pieter Sonneveld.   

Abstract

The clinical data on the efficacy and toxicity of bortezomib as treatment for multiple myeloma patients are restricted to prospective phase II studies in expert myeloma centers. Here we report a multi-institutional analysis of the efficacy and toxicity of bortezomib in patients with relapsed or refractory multiple myeloma who were treated in community centers in a compassionate need program.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15996946

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  6 in total

1.  Hypoxia Promotes Synergy between Mitomycin C and Bortezomib through a Coordinated Process of Bcl-xL Phosphorylation and Mitochondrial Translocation of p53.

Authors:  Xinxin Song; Ashok-Kumar Dilly; Haroon Asif Choudry; David L Bartlett; Yong Tae Kwon; Yong J Lee
Journal:  Mol Cancer Res       Date:  2015-09-09       Impact factor: 5.852

2.  Micelle-encapsulated thiostrepton as an effective nanomedicine for inhibiting tumor growth and for suppressing FOXM1 in human xenografts.

Authors:  Ming Wang; Andrei L Gartel
Journal:  Mol Cancer Ther       Date:  2011-09-08       Impact factor: 6.261

3.  Importance of Compliance With Guidelines for the Prevention of Varicella-Zoster Virus Reactivation in Multiple Myeloma.

Authors:  Yasukata Ohashi; Megumi Yatabe; Daisuke Niijima; Arina Imamura; Yoshiyuki Nagayama; Kentaro Otsuka; Yutaka Yachi; Hironori Ueno; Takahiro Yano; Nobuaki Mori; Koji Higai; Akihiro Yokoyama
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

4.  Bortezomib: the evidence of its clinical impact in multiple myeloma.

Authors:  Simon Lancaster
Journal:  Core Evid       Date:  2006-06-30

5.  Endoplasmic Reticulum-Targeted Subunit Toxins Provide a New Approach to Rescue Misfolded Mutant Proteins and Revert Cell Models of Genetic Diseases.

Authors:  Humaira Adnan; Zhenbo Zhang; Hyun-Joo Park; Chetankumar Tailor; Clare Che; Mustafa Kamani; George Spitalny; Beth Binnington; Clifford Lingwood
Journal:  PLoS One       Date:  2016-12-09       Impact factor: 3.240

Review 6.  Novel Perspectives in Pseudomyxoma Peritonei Treatment.

Authors:  Antonio Sommariva; Marco Tonello; Giulia Rigotto; Nayana Lazzari; Pierluigi Pilati; Maria Luisa Calabrò
Journal:  Cancers (Basel)       Date:  2021-11-27       Impact factor: 6.639
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.